Dianthus Therapeutics, Inc. /DE/
Dianthus Therapeutics, Inc. /DE/ is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy on December 15, 2026. There are 3 upcoming events on record.
Cash runway is approximately 11.5 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 15, 2026 | A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy | Trial Milestone | Phase 2 |
| December 15, 2028 | A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE) | Trial Milestone | Phase 3 |
| December 31, 2028 | A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) | Trial Milestone | Phase 3 |
Track DNTH alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open DNTH in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| August 4, 2026 | Quarterly results filed (8-K) | Earnings | — |
| June 12, 2026 | 8-K filed: Other event | Filing | — |
| May 5, 2026 | Quarterly results filed (8-K) | Earnings | — |
| March 26, 2026 | 8-K filed: Other event | Filing | — |
| March 12, 2026 | 8-K filed: Material agreement | Corporate | — |
| March 9, 2026 | Quarterly results filed (8-K) | Earnings | — |
| January 12, 2026 | Quarterly results filed (8-K) | Earnings | — |
| November 5, 2025 | Quarterly results filed (8-K) | Earnings | — |
| November 3, 2025 | 8-K filed: Other event | Filing | — |
| October 16, 2025 | Quarterly results filed (8-K) | Earnings | — |
| September 11, 2025 | 8-K filed: Material agreement | Corporate | — |
| September 8, 2025 | 8-K filed: Reg FD disclosure, Other event | Filing | — |
| August 7, 2025 | Quarterly results filed (8-K) | Earnings | — |
| July 28, 2025 | A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) | Trial Milestone | Phase 2 |
| May 22, 2025 | 8-K filed: Leadership change | Corporate | — |
| May 12, 2025 | Quarterly results filed (8-K) | Earnings | — |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.